Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on HOPO Therapeutics — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

HOPO Therapeutics Awarded $226 Million Contract from BARDA for Advanced Development of Oral Decorporation Agent

Oct 28, 2024•over 1 year ago

Contract Type

contract

BerkeleyManufacturingBiotechnology

Description

HOPO Therapeutics, Inc. has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of the drug candidate HOPO-101 as a medical countermeasure against radiological threats. The funds will be used for toxicology and pharmacology studies, manufacturing activities, and nonclinical research in heavy metal poisoning, with additional funding available for later-stage development upon agreement between BARDA and HOPO.

Company Information

Company

HOPO Therapeutics

Location

Berkeley, California, United States

About

HOPO Therapeutics, Inc. is a company focused on developing decorporation agents for heavy metal toxicity, with a mission to provide rapid access to treatment for an exposed population during radiological or nuclear disasters.

Predictive Intelligence
Strategic

ML-powered predictions for HOPO Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months